WO2002088716A3 - Polymer marker having a molecular weight of 1518 daltons - Google Patents

Polymer marker having a molecular weight of 1518 daltons Download PDF

Info

Publication number
WO2002088716A3
WO2002088716A3 PCT/CA2002/000577 CA0200577W WO02088716A3 WO 2002088716 A3 WO2002088716 A3 WO 2002088716A3 CA 0200577 W CA0200577 W CA 0200577W WO 02088716 A3 WO02088716 A3 WO 02088716A3
Authority
WO
WIPO (PCT)
Prior art keywords
daltons
molecular weight
absence
disease state
biopolymers
Prior art date
Application number
PCT/CA2002/000577
Other languages
French (fr)
Other versions
WO2002088716A2 (en
Inventor
George Jackowski
Brad Thatcher
John Marshall
Jason Yantha
Tammy Vrees
Original Assignee
Syn X Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syn X Pharma Inc filed Critical Syn X Pharma Inc
Priority to AU2002308469A priority Critical patent/AU2002308469A1/en
Publication of WO2002088716A2 publication Critical patent/WO2002088716A2/en
Publication of WO2002088716A3 publication Critical patent/WO2002088716A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Abstract

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verfiable within a particular samole. The cohort of biopolymers verified within such a sample is then viewed with reference to their abbility to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.
PCT/CA2002/000577 2001-04-30 2002-04-25 Polymer marker having a molecular weight of 1518 daltons WO2002088716A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002308469A AU2002308469A1 (en) 2001-04-30 2002-04-25 Polymer marker having a molecular weight of 1518 daltons

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/845,765 2001-04-30
US09/845,765 US20040198950A1 (en) 2001-04-30 2001-04-30 Biopolymer marker indicative of disease state having a molecular weight of 1518 daltons

Publications (2)

Publication Number Publication Date
WO2002088716A2 WO2002088716A2 (en) 2002-11-07
WO2002088716A3 true WO2002088716A3 (en) 2003-10-23

Family

ID=25296050

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/000577 WO2002088716A2 (en) 2001-04-30 2002-04-25 Polymer marker having a molecular weight of 1518 daltons

Country Status (3)

Country Link
US (2) US20040198950A1 (en)
AU (1) AU2002308469A1 (en)
WO (1) WO2002088716A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002336845A1 (en) * 2001-11-23 2003-06-10 Syn.X Pharma, Inc. Globin biopolymer markers indicative of insulin resistance
US7848460B2 (en) * 2007-07-12 2010-12-07 Telefonaktiebolaget Lm Ericsson (Publ) Interference suppression method and apparatus

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014580A1 (en) * 1994-11-07 1996-05-17 Merck & Co., Inc. Assay for marker of human polymorphonuclear leukocyte elastase activity
US5538897A (en) * 1994-03-14 1996-07-23 University Of Washington Use of mass spectrometry fragmentation patterns of peptides to identify amino acid sequences in databases
US5817768A (en) * 1995-06-07 1998-10-06 The New York Blood Center, Inc. Monospecific antibodies against a subunit of fibrinogen
US5827659A (en) * 1995-05-19 1998-10-27 Perseptive Biosystems, Inc. Methods and apparatus for sequencing polymers using mass spectrometry
WO2000009562A1 (en) * 1998-08-12 2000-02-24 The New York Blood Center, Inc. Novel cleaved fragments of fibrinogen
WO2000049410A2 (en) * 1999-02-16 2000-08-24 The Government Of The United States Of America, As Represented By The Secretary Department Of Health & Human Services, The National Institutes Of Health Lcm (laser capture microdissection) for cellular protein analysis
WO2001005422A2 (en) * 1999-07-15 2001-01-25 Biomerieux Stelhys Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease
WO2001075454A2 (en) * 2000-04-03 2001-10-11 Oxford Glycosciences (Uk) Ltd. Diagnosis and treatment of alzheimer's disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3809504C1 (en) * 1988-03-22 1989-09-21 Bruker - Franzen Analytik Gmbh, 2800 Bremen, De
JPH04501468A (en) 1989-05-19 1992-03-12 フェン，ジョン，ビー Methods for determining the molecular weight of multiply charged ions and large molecules
EP0664884A4 (en) 1992-05-29 1997-05-02 Univ Rockefeller Method and product for the sequence determination of peptides using a mass spectrometer.
US6020208A (en) * 1994-05-27 2000-02-01 Baylor College Of Medicine Systems for surface-enhanced affinity capture for desorption and detection of analytes
WO1996036986A1 (en) 1995-05-19 1996-11-21 Perseptive Biosystems, Inc. Methods and apparatus for sequencing polymers with a statistical certainty using mass spectrometry
PT922226E (en) 1996-08-13 2003-07-31 Biovision Ag PROCESS FOR THE EVALUATION OF THE STATE OF AN ORGANISM THROUGH PEPTIDE MEDICATION
AU2683699A (en) 1998-02-18 1999-09-06 Harbor-Ucla Research And Education Institute Antimicrobial peptides and derived metapeptides
CN1262337C (en) * 2000-11-16 2006-07-05 赛弗根生物系统股份有限公司 Method for analyzing mass spectra
US20040121306A1 (en) * 2002-12-20 2004-06-24 Peter Kupchak Method of confirming the presence of myocardial infarction

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5538897A (en) * 1994-03-14 1996-07-23 University Of Washington Use of mass spectrometry fragmentation patterns of peptides to identify amino acid sequences in databases
WO1996014580A1 (en) * 1994-11-07 1996-05-17 Merck & Co., Inc. Assay for marker of human polymorphonuclear leukocyte elastase activity
US5827659A (en) * 1995-05-19 1998-10-27 Perseptive Biosystems, Inc. Methods and apparatus for sequencing polymers using mass spectrometry
US5817768A (en) * 1995-06-07 1998-10-06 The New York Blood Center, Inc. Monospecific antibodies against a subunit of fibrinogen
WO2000009562A1 (en) * 1998-08-12 2000-02-24 The New York Blood Center, Inc. Novel cleaved fragments of fibrinogen
WO2000049410A2 (en) * 1999-02-16 2000-08-24 The Government Of The United States Of America, As Represented By The Secretary Department Of Health & Human Services, The National Institutes Of Health Lcm (laser capture microdissection) for cellular protein analysis
WO2001005422A2 (en) * 1999-07-15 2001-01-25 Biomerieux Stelhys Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease
WO2001075454A2 (en) * 2000-04-03 2001-10-11 Oxford Glycosciences (Uk) Ltd. Diagnosis and treatment of alzheimer's disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE ENTREZ-PROTEIN [online] National Center for Biotechnology Information (NCBI); 15 June 2002 (2002-06-15), "Fibrinogen alpha", XP002211975, retrieved from WWW.NCBI.NLM.NIH.GOV accession no. P02671 *
SCHARFSTEIN J S ET AL: "Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. TIMI-5 Investigators. Thrombolysis in Myocardial Infarction.", THE AMERICAN JOURNAL OF CARDIOLOGY. UNITED STATES 1 SEP 1996, vol. 78, no. 5, 1 September 1996 (1996-09-01), pages 503 - 510, XP002211974, ISSN: 0002-9149 *
SOBEL JOAN H ET AL: "Antipeptide monoclonal antibodies to defined fibrinogen Aalpha chain regions: Anti-Aalpha 487-498, a structural probe for fibrinogenolysis.", BLOOD, vol. 91, no. 5, 1 March 1998 (1998-03-01), pages 1590 - 1598, XP002211973, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
US20050287599A1 (en) 2005-12-29
US7125726B2 (en) 2006-10-24
WO2002088716A2 (en) 2002-11-07
US20040198950A1 (en) 2004-10-07
AU2002308469A1 (en) 2002-11-11

Similar Documents

Publication Publication Date Title
WO2002088722A3 (en) Biopolymer marker having a molecular weight of 1350 daltons
WO2004004647A3 (en) Nanoparticle polyanion conjugates and methods of use thereof in detecting analytes
WO2002088726A3 (en) Biopolymer marker having a molecular weight of 1449 daltons
WO2002088742A3 (en) Biopolymer marker having a molecular weight of 2937 daltons
WO2003060470A3 (en) Breast cancer expression profiling
WO2002088743A3 (en) Biopolymer marker having a molecular weight of 1097 daltons
WO2002088174A3 (en) Biopolymer marker having a molecular weight of 1865 daltons
WO2003046572A3 (en) Biopolymer markers predictive of alzheimers disease
WO2002088715A3 (en) Biopolymer marker having a molecular weight of 1465 daltons
WO2002088711A3 (en) Biopolymer marker indicative of disease state having a molecular weight of 2021 daltons
WO2002088719A3 (en) Biopolymer marker having a molecular weight of 1424 daltons
WO2002088747A3 (en) Biopolymer marker having a molecular weight of 1845 daltons
WO2006089161A3 (en) Immunostimulating polyphosphazene compounds
WO2002088745A3 (en) Biopolymer marker having a molecular weight of 2267 daltons
WO2002088724A3 (en) Biopolymer marker having a molecular weight of 1896 daltons
WO2002088727A3 (en) Biopolymer marker having a molecular weight of 1690 daltons
WO2002088721A3 (en) Biopolymer marker having a molecular weight of 1206 daltons
WO2002088728A3 (en) Biopolymer marker having a molecular weight of 1020 daltons
WO2002088712A3 (en) Biopolymer marker state having a molecular weight of 1777 daltons
WO2002088731A3 (en) Biopolymer marker having a molecular weight of 1211 daltons
WO2002088716A3 (en) Polymer marker having a molecular weight of 1518 daltons
WO2002088720A3 (en) Biopolymer marker having a molecular weight of 1348 daltons
WO2002088729A3 (en) Biopolymer marker having a molecular weight of 1562 daltons
WO2002088707A3 (en) Biopolymer marker having a molecular weight of 1998 daltons
WO2002088730A3 (en) Biopolymer marker having a molecular weight of 1525 daltons

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP